CASI Pharmeceuticals

MARQIBO

Marqibo

Marqibo® is a novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor. Marqibo is approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Please see Marqibo product and safety information.

Since MARQIBO is already approved in the U.S. and marketed by our licensor, we expect that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical stage drugs. We submitted an import drug registration is pending with CFDA.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Kinase Inhibitor Demonstrates Efficacy in a Patient-Derived Xenograft Model of Fibrolamellar Hepatocellular Carcinoma featuring DNAJB1-PRKACA Fusion

Download →

Poster

Evaluation Of ENMD-2076 In Combination With Anti-PD1 In Syngeneic Cancer Models

Download →